文摘
To examine the safety and effectiveness of buprenorphine + naloxone sublingual tablets (BUP, as Suboxonep>®p>) provided after administration of extended-release injectable naltrexone (XR-NTX, as Vivitrolp>®p>) to reduce cocaine use in participants who met DSM-IV criteria for cocaine dependence and past or current opioid dependence or abuse.